DURING a mid-stage trial, Eli Lilly's experimental pill orforglipron has led to 14.7% weight loss after 36 weeks, for people who were obese or overweight, setting a marker in the race to develop effective oral obesity drugs, said researchers last week in Reuters.
Results from a different trial, also presented in San Diego at the annual meeting of the American Diabetes Association, showed that Lilly's injected drug Mounjaro helped people with type 2 diabetes who were also obese or overweight lose an average of 15% of their body weight, or 14.8kg.
Lilly said the safety profile of orforglipron was similar to other incretin-based therapies.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jun 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
